Qiagen (NYSE:QGEN) Issues FY24 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of at least $2.19 for the period, compared to the consensus estimate of $2.15. The company issued revenue guidance of at least $1.985 billion, compared to the consensus revenue estimate of $1.97 billion.

Analysts Set New Price Targets

QGEN has been the topic of a number of research analyst reports. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Robert W. Baird raised their price target on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Trading Down 0.2 %

Shares of NYSE:QGEN traded down $0.08 on Wednesday, reaching $43.87. 1,578,638 shares of the company traded hands, compared to its average volume of 1,170,399. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The business’s 50-day simple moving average is $44.15 and its 200 day simple moving average is $43.70. The stock has a market capitalization of $10.01 billion, a P/E ratio of 142.49, a price-to-earnings-growth ratio of 3.33 and a beta of 0.41. Qiagen has a 52 week low of $37.51 and a 52 week high of $47.44.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.